Last updated: September 22, 2023
Sponsor: ModernaTX, Inc.
Overall Status: Active - Recruiting
Phase
3
Condition
Vaccines
Covid-19
Treatment
N/AClinical Study ID
TX318207
Ages 12-99 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Investigator's assessment that the participant understands and is willing and physically able to comply with protocol-mandated follow-up, including all procedures.
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to the first injection, and agreement to continue adequate contraception or abstinence through 90 days following the vaccine administration.
- Has previously received a primary series of an authorized/approved COVID-19 vaccine. For participants ≥ 18 years of age, at least 1 booster dose must have also been received. Proof of prior vaccination is required. A heterologous vaccine regimen is acceptable.
Exclusion
Exclusion Criteria:
- Has had close contact, as defined by the Centers for Disease Control and Prevention (CDC), with someone who had a SARS-CoV-2 infection in the past 14 days, or COVID-19 in the past 10 days.
- Participant is acutely ill or febrile (temperature ≥ 38.0 degree Celsius [°C]/100.4 degree Fahrenheit [°F]) 72 hours prior to or at the Screening Visit or Day 1.
- Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 181 days prior to Screening (for corticosteroids ≥ 10 mg/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
- Has received or plans to receive any licensed vaccine ≤60 days prior to the study injection (Day 1) or plans to receive a licensed vaccine within 60 days after the study injection.
- Has received systemic immunoglobulins or blood products within 90 days prior to the Screening Visit or plans to receive during the study.
- Has donated ≥ 450 milliliters (mL) of blood products within 28 days prior to the Screening Visit or plans to donate blood products during the study.
- Has participated in an interventional clinical study within 28 days prior to the Screening Visit based on the medical history interview or plans to do so while participating in this study.
Study Design
Study Start date:
Estimated Completion Date:
Study Description
Connect with a study center
AMR Kansas City (formerly Center for Pharmaceutical Research)
Kansas City, Missouri 64114
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.